Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Reply to E. Laffon et al.

Bailly C, Carlier T, Kraeber-Bodéré F, Le Gouill S, Bodet-Milin C.

Haematologica. 2020 Jan;105(1):e42. doi: 10.3324/haematol.2019.240523. No abstract available.

2.

Good clinical practice recommendations for the use of PET/CT in oncology.

Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, Coriat R, Hindie E, Taieb D, Tabarin A, Girard A, Grellier JF, Brenot-Rossi I, Groheux D, Rousseau C, Deandreis D, Alberini JL, Bodet-Milin C, Itti E, Casasnovas O, Kraeber-Bodere F, Moreau P, Philip A, Balleyguier C, Luciani A, Cachin F.

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):28-50. doi: 10.1007/s00259-019-04553-8. Epub 2019 Oct 21.

PMID:
31637482
3.

Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture.

Bailly C, Bodet-Milin C, Bourgeois M, Gouard S, Ansquer C, Barbaud M, Sébille JC, Chérel M, Kraeber-Bodéré F, Carlier T.

Cancers (Basel). 2019 Aug 31;11(9). pii: E1282. doi: 10.3390/cancers11091282. Review.

4.

Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.

Bailly C, Carlier T, Berriolo-Riedinger A, Casasnovas O, Gyan E, Meignan M, Moreau A, Burroni B, Djaileb L, Gressin R, Devillers A, Lamy T, Thieblemont C, Hermine O, Kraeber-Bodéré F, Le Gouill S, Bodet-Milin C.

Haematologica. 2020 Jan;105(1):e33-e36. doi: 10.3324/haematol.2019.223016. Epub 2019 Aug 1. No abstract available.

5.

Potential for Nuclear Medicine Therapy for Glioblastoma Treatment.

Bailly C, Vidal A, Bonnemaire C, Kraeber-Bodéré F, Chérel M, Pallardy A, Rousseau C, Garcion E, Lacoeuille F, Hindré F, Valable S, Bernaudin M, Bodet-Milin C, Bourgeois M.

Front Pharmacol. 2019 Jul 10;10:772. doi: 10.3389/fphar.2019.00772. eCollection 2019. Review.

6.

Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis.

Morvan L, Carlier T, Jamet B, Bailly C, Bodet-Milin C, Moreau P, Kraeber-Bodéré F, Mateus D.

Int J Comput Assist Radiol Surg. 2020 Jan;15(1):129-139. doi: 10.1007/s11548-019-02015-y. Epub 2019 Jun 29. Review.

PMID:
31256359
7.

Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches.

Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, Lacoeuille F, Drui D, Arlicot N, Goldenberg DM, Faivre-Chauvet A, Barbet J, Rousseau C, Kraeber-Bodéré F.

Front Med (Lausanne). 2019 Jun 4;6:124. doi: 10.3389/fmed.2019.00124. eCollection 2019. Review.

8.

What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model.

Bailly C, Gouard S, Guérard F, Chalopin B, Carlier T, Faivre-Chauvet A, Remaud-Le Saëc P, Bourgeois M, Chouin N, Rbah-Vidal L, Tripier R, Haddad F, Kraeber-Bodéré F, Bodet-Milin C, Chérel M.

Int J Mol Sci. 2019 May 24;20(10). pii: E2564. doi: 10.3390/ijms20102564.

9.

[18F]-Fludarabine for Hematological Malignancies.

Barré L, Hovhannisyan N, Bodet-Milin C, Kraeber-Bodéré F, Damaj G.

Front Med (Lausanne). 2019 Apr 17;6:77. doi: 10.3389/fmed.2019.00077. eCollection 2019. Review.

10.

Interest of FDG-PET in the Management of Mantle Cell Lymphoma.

Bailly C, Carlier T, Touzeau C, Arlicot N, Kraeber-Bodéré F, Le Gouill S, Bodet-Milin C.

Front Med (Lausanne). 2019 Apr 9;6:70. doi: 10.3389/fmed.2019.00070. eCollection 2019. Review.

11.

Interest of Pet Imaging in Multiple Myeloma.

Jamet B, Bailly C, Carlier T, Touzeau C, Nanni C, Zamagni E, Barré L, Michaud AV, Chérel M, Moreau P, Bodet-Milin C, Kraeber-Bodéré F.

Front Med (Lausanne). 2019 Apr 9;6:69. doi: 10.3389/fmed.2019.00069. eCollection 2019. Review.

12.

18F-FDG PET/CT in multiple myeloma: critical insights and future directions.

Bailly C, Carlier T, Jamet B, Touzeau C, Moreau P, Kraeber-Bodéré F, Bodet-Milin C.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1048-1050. doi: 10.1007/s00259-019-04279-7. Epub 2019 Feb 15. No abstract available.

PMID:
30770949
13.

[Update of the recommendations of good clinical practice for the use of PET in oncology].

Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, Coriat R, Hindie E, Taieb D, Tabarin A, Girard A, Grellier JF, Brenot-Rossi I, Groheux D, Rousseau C, Deandreis D, Alberini JL, Bodet-Milin C, Itti E, Casasnovas O, Kraeber-Bodere F, Moreau P, Philip A, Balleyguier C, Lucian A, Cachin F.

Bull Cancer. 2019 Mar;106(3):262-274. doi: 10.1016/j.bulcan.2019.01.002. Epub 2019 Jan 23. French.

PMID:
30683308
14.

Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients.

Bouard L, Bodet-Milin C, Bailly C, Guillaume T, Peterlin P, Garnier A, Bourgeois AL, Mahé B, Dubruille V, Blin N, Touzeau C, Gastinne T, Lok A, Bonnet A, Béné MC, Gouill SL, Moreau P, Kraeber-Bodéré F, Chevallier P.

Biol Blood Marrow Transplant. 2019 May;25(5):906-911. doi: 10.1016/j.bbmt.2018.11.019. Epub 2018 Nov 24.

PMID:
30481598
15.

Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study.

Bailly C, Carlier T, Jamet B, Eugene T, Touzeau C, Attal M, Hulin C, Facon T, Leleu X, Perrot A, Garderet L, Macro M, Caillot D, Moreau P, Kraeber-Bodéré F, Bodet-Milin C.

Clin Cancer Res. 2018 Nov 1;24(21):5219-5224. doi: 10.1158/1078-0432.CCR-18-0741. Epub 2018 Aug 1.

16.

Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT.

Foubert F, Gouard S, Saï-Maurel C, Chérel M, Faivre-Chauvet A, Goldenberg DM, Barbet J, Bailly C, Bodet-Milin C, Carlier T, Kraeber-Bodéré F, Touchefeu Y, Frampas E.

Oncotarget. 2018 Jun 8;9(44):27502-27513. doi: 10.18632/oncotarget.25514. eCollection 2018 Jun 8.

17.

Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients.

Jamet B, Bailly C, Carlier T, Planche L, Touzeau C, Kraeber-Bodéré F, Moreau P, Bodet-Milin C.

Leuk Lymphoma. 2019 Jan;60(1):222-225. doi: 10.1080/10428194.2018.1459602. Epub 2018 May 2. No abstract available.

PMID:
29717914
18.

Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma.

Bailly C, Gouard S, Lacombe M, Remaud-Le Saëc P, Chalopin B, Bourgeois M, Chouin N, Tripier R, Halime Z, Haddad F, Faivre-Chauvet A, Kraeber-Bodéré F, Chérel M, Bodet-Milin C.

Oncotarget. 2018 Jan 3;9(10):9061-9072. doi: 10.18632/oncotarget.23886. eCollection 2018 Feb 6.

19.

18F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients.

Chantepie S, Hovhannisyan N, Guillouet S, Pelage JP, Ibazizene M, Bodet-Milin C, Carlier T, Gac AC, Réboursière E, Vilque JP, Kraeber-Bodéré F, Manrique A, Damaj G, Leporrier M, Barré L.

J Nucl Med. 2018 Sep;59(9):1380-1385. doi: 10.2967/jnumed.117.206920. Epub 2018 Feb 1.

20.

Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.

Bailly C, Leforestier R, Campion L, Thebaud E, Moreau A, Kraeber-Bodere F, Carlier T, Bodet-Milin C.

PLoS One. 2017 Aug 25;12(8):e0183841. doi: 10.1371/journal.pone.0183841. eCollection 2017.

21.

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.

Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa AM, Laribi K, Hulin C, Perrot A, Marit G, Eveillard JR, Caillon F, Bodet-Milin C, Pegourie B, Dorvaux V, Chaleteix C, Anderson K, Richardson P, Munshi NC, Avet-Loiseau H, Gaultier A, Nguyen JM, Dupas B, Frampas E, Kraeber-Bodere F.

J Clin Oncol. 2017 Sep 1;35(25):2911-2918. doi: 10.1200/JCO.2017.72.2975. Epub 2017 Jul 7.

22.

Radioimmunoconjugates for treating cancer: recent advances and current opportunities.

Bourgeois M, Bailly C, Frindel M, Guerard F, Chérel M, Faivre-Chauvet A, Kraeber-Bodéré F, Bodet-Milin C.

Expert Opin Biol Ther. 2017 Jul;17(7):813-819. doi: 10.1080/14712598.2017.1322577. Epub 2017 May 4. Review.

PMID:
28438082
23.

Report of the 6th International Workshop on PET in lymphoma.

Nanni C, Cottereau AS, Lopci E, Bodet-Milin C, Coronado M, Pro B, Kim WS, Trotman J, Barrington S, Duhrsen U, Vander Borght T, Zamagni E, Kraeber-Bodéré F, Messiou C, Rahmouni A, Buvat I, Andre M, Hertzberg M, Oyen W, Casasnovas O, Luminari S, Garderet L, Montravers F, Kobe C, Kluge R, Versari A, Zucca E, Moreau P, Cheson B, Haioun C, Gallamini A, Meignan M.

Leuk Lymphoma. 2017 Oct;58(10):2298-2303. doi: 10.1080/10428194.2017.1298752. Epub 2017 Mar 7.

PMID:
28264597
24.

PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.

Bailly C, Leforestier R, Jamet B, Carlier T, Bourgeois M, Guérard F, Touzeau C, Moreau P, Chérel M, Kraeber-Bodéré F, Bodet-Milin C.

Int J Mol Sci. 2017 Feb 18;18(2). pii: E445. doi: 10.3390/ijms18020445. Review.

25.

Pretargeting for imaging and therapy in oncological nuclear medicine.

Bailly C, Bodet-Milin C, Rousseau C, Faivre-Chauvet A, Kraeber-Bodéré F, Barbet J.

EJNMMI Radiopharm Chem. 2017;2(1):6. doi: 10.1186/s41181-017-0026-8. Epub 2017 Jun 6. Review.

26.

Immuno-PET for Clinical Theranostic Approaches.

Bailly C, Cléry PF, Faivre-Chauvet A, Bourgeois M, Guérard F, Haddad F, Barbet J, Chérel M, Kraeber-Bodéré F, Carlier T, Bodet-Milin C.

Int J Mol Sci. 2016 Dec 28;18(1). pii: E57. doi: 10.3390/ijms18010057. Review.

27.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P.

Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8.

PMID:
27964867
28.

Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials.

Bailly C, Bodet-Milin C, Couespel S, Necib H, Kraeber-Bodéré F, Ansquer C, Carlier T.

PLoS One. 2016 Jul 28;11(7):e0159984. doi: 10.1371/journal.pone.0159984. eCollection 2016.

29.

Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.

Bodet-Milin C, Faivre-Chauvet A, Carlier T, Rauscher A, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F.

J Nucl Med. 2016 Oct;57(10):1505-1511. Epub 2016 May 26.

30.

Radioimmunotherapy for Treatment of Acute Leukemia.

Bodet-Milin C, Kraeber-Bodéré F, Eugène T, Guérard F, Gaschet J, Bailly C, Mougin M, Bourgeois M, Faivre-Chauvet A, Chérel M, Chevallier P.

Semin Nucl Med. 2016 Mar;46(2):135-46. doi: 10.1053/j.semnuclmed.2015.10.007. Review.

PMID:
26897718
31.

(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.

Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, Huguet F, Hunault M, Marcais A, Gaschet J, Cherel M, Guillaume T, Delaunay J, Peterlin P, Eveillard M, Thomas X, Ifrah N, Lapusan S, Bodet-Milin C, Barbet J, Faivre-Chauvet A, Ferrer L, Bene MC, Le Houerou C, Goldenberg DM, Wegener WA, Kraeber-Bodéré F.

Lancet Haematol. 2015 Mar;2(3):e108-17. doi: 10.1016/S2352-3026(15)00020-4. Epub 2015 Feb 25.

PMID:
26687796
32.

Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients.

Bodet-Milin C, Ferrer L, Rauscher A, Masson D, Rbah-Vidal L, Faivre-Chauvet A, Cerato E, Rousseau C, Hureaux J, Couturier O, Salaün PY, Goldenberg DM, Sharkey RM, Kraeber-Bodéré F, Barbet J.

Front Med (Lausanne). 2015 Nov 27;2:84. doi: 10.3389/fmed.2015.00084. eCollection 2015.

33.

A pretargeting system for tumor PET imaging and radioimmunotherapy.

Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Frampas E, Faivre-Chauvet A, Rauscher A, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J.

Front Pharmacol. 2015 Mar 31;6:54. doi: 10.3389/fphar.2015.00054. eCollection 2015. Review.

34.

Tumor immunotargeting using innovative radionuclides.

Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Mathieu C, Guérard F, Frampas E, Carlier T, Chouin N, Haddad F, Chatal JF, Faivre-Chauvet A, Chérel M, Barbet J.

Int J Mol Sci. 2015 Feb 11;16(2):3932-54. doi: 10.3390/ijms16023932. Review.

35.

Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy.

Bailly C, Eugène T, Couec ML, Strullu M, Frampas E, Campion L, Kraeber-Bodéré F, Bodet-Milin C.

Front Med (Lausanne). 2014 Dec 16;1:54. doi: 10.3389/fmed.2014.00054. eCollection 2014.

36.

Radioimmunoconjugates for the treatment of cancer.

Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Eugène T, Pallardy A, Frampas E, Carlier T, Ferrer L, Gaschet J, Davodeau F, Gestin JF, Faivre-Chauvet A, Barbet J, Chérel M.

Semin Oncol. 2014 Oct;41(5):613-22. doi: 10.1053/j.seminoncol.2014.07.004. Epub 2014 Jul 22. Review.

PMID:
25440606
37.

Clinical NECR in 18F-FDG PET scans: optimization of injected activity and variable acquisition time. Relationship with SNR.

Carlier T, Ferrer L, Necib H, Bodet-Milin C, Rousseau C, Kraeber-Bodéré F.

Phys Med Biol. 2014 Nov 7;59(21):6417-30. doi: 10.1088/0031-9155/59/21/6417. Epub 2014 Oct 8.

PMID:
25295879
38.

Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.

Illidge TM, Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, Ryder WD, Le Gouill S, Jardin F, Tipping J, Zivanovic M, Kraeber-Bodere F, Bardies M, Bodet-Milin C, Malek E, Huglo D, Morschhauser F.

J Clin Oncol. 2014 Jan 20;32(3):212-8. doi: 10.1200/JCO.2013.50.3110. Epub 2013 Dec 2.

PMID:
24297953
39.

18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study.

Bodet-Milin C, Lacombe M, Malard F, Lestang E, Cahu X, Chevallier P, Guillaume T, Delaunay J, Brissot E, Moreau P, Kraeber-Bodere F, Mohty M.

Bone Marrow Transplant. 2014 Jan;49(1):131-7. doi: 10.1038/bmt.2013.144. Epub 2013 Sep 30.

PMID:
24076550
40.

BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.

Chevallier P, Bodet-Milin C, Robillard N, Eugene T, Menard A, Le Houerou C, Guillaume T, Delaunay J, Escoffre-Barbe M, Wegener WA, Goldenberg DM, Kraeber-Bodéré F.

Eur J Haematol. 2013 Dec;91(6):552-6. doi: 10.1111/ejh.12183. Epub 2013 Sep 12.

PMID:
23927500
41.

Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma.

Bodet-Milin C, Ferrer L, Pallardy A, Eugène T, Rauscher A, Alain Faivre-Chauvet, Barbet J, Kraeber-Bodéré F.

Front Oncol. 2013 Jul 11;3:177. doi: 10.3389/fonc.2013.00177. eCollection 2013.

42.

Improvement of radioimmunotherapy using pretargeting.

Frampas E, Rousseau C, Bodet-Milin C, Barbet J, Chatal JF, Kraeber-Bodéré F.

Front Oncol. 2013 Jun 20;3:159. doi: 10.3389/fonc.2013.00159. eCollection 2013.

43.

Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT.

Carlier T, Eugène T, Bodet-Milin C, Garin E, Ansquer C, Rousseau C, Ferrer L, Barbet J, Schoenahl F, Kraeber-Bodéré F.

EJNMMI Res. 2013 Feb 17;3(1):11. doi: 10.1186/2191-219X-3-11.

44.

Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma.

Ferrer L, Malek E, Bodet-Milin C, Legouill S, Prangère T, Robu D, Jeans S, Tipping J, Huglo D, Carpentier P, Illidge T, Kraeber-Boderé F, Morschhauser F, Bardiès M.

Q J Nucl Med Mol Imaging. 2012 Dec;56(6):529-37.

PMID:
23358406
45.

Staging and monitoring in the treatment of lymphomas.

Dupas B, Augeul-Meunier K, Frampas E, Bodet-Milin C, Gastinne T, Le Gouill S.

Diagn Interv Imaging. 2013 Feb;94(2):145-57. doi: 10.1016/j.diii.2012.12.009. Epub 2013 Jan 16.

46.

The role of FDG-PET scanning in assessing lymphoma in 2012.

Bodet-Milin C, Eugène T, Gastinne T, Bailly C, Le Gouill S, Dupas B, Kraeber-Bodéré F.

Diagn Interv Imaging. 2013 Feb;94(2):158-68. doi: 10.1016/j.diii.2012.12.005. Epub 2013 Jan 5.

47.

FDG-PET in the evaluation of myeloma in 2012.

Bodet-Milin C, Eugène T, Bailly C, Lacombe M, Frampas E, Dupas B, Moreau P, Kraeber-Bodéré F.

Diagn Interv Imaging. 2013 Feb;94(2):184-9. doi: 10.1016/j.diii.2012.12.006. Epub 2013 Jan 1.

48.

¹⁸F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas.

Eugene T, Corradini N, Carlier T, Dupas B, Leux C, Bodet-Milin C.

Nucl Med Commun. 2012 Oct;33(10):1089-95. doi: 10.1097/MNM.0b013e328356741f.

PMID:
22929116
49.

FDG-PET in Follicular Lymphoma Management.

Bodet-Milin C, Eugène T, Gastinne T, Frampas E, Le Gouill S, Kraeber-Bodéré F.

J Oncol. 2012;2012:370272. doi: 10.1155/2012/370272. Epub 2012 Jul 30.

50.

Vertebral osteomyelitis: an unusual presentation of Bartonella henselae infection.

Graveleau J, Grossi O, Lefebvre M, Redon H, Caignon JM, Pallardy A, Bodet-Milin C, Néel A, Hamidou MA.

Semin Arthritis Rheum. 2011 Dec;41(3):511-6. doi: 10.1016/j.semarthrit.2011.04.011. Epub 2011 Aug 15.

PMID:
21840042

Supplemental Content

Loading ...
Support Center